U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Enforcement Activities | FDA
  5. Regulatory Actions Against Ranbaxy and Sun Pharma
  1. Enforcement Activities | FDA

Regulatory Actions Against Ranbaxy and Sun Pharma

The following is a list of regulatory actions related to Ranbaxy Laboratories (Ranbaxy) and Sun Pharmaceutical Industries (Sun Pharma). Sun Pharma announced the acquisition of Ranbaxy in 2014, and the merger was completed in March 2015.

Actions taken under consent decree regarding facility in Toansa, India
Actions taken under consent decree regarding facility in Mohali, India
Department of Justice actions against Ranbaxy
  • DOJ News Release: Generic drug manufacturer Ranbaxy pleads guilty and agrees to pay $500 million to resolve false claims allegations, CGMP violations and false statements to the FDA (5/13/2013)
  • FDA News Release: Department of Justice files consent decree of permanent injunction against Ranbaxy (1/25/2012)
Application Integrity Policy action for Ranbaxy’s facility in Paonta Sahib, India
Import alert for Ranbaxy’s facilities in Dewas and Paonta Sahib, India
Additional warning letters

 

 
Back to Top